Trends in Conventional Heart Failure Therapy in a Real-World Multinational ATTR-CA Cohort

Background: Conventional HF treatment in transthyretin cardiac amyloidosis (ATTR-CA) resulting in restrictive cardiomyopathy is debated due to absent trial evidence in this specific sub-population of heart failure (HF) patients. Current European Society of Cardiology guidelines recommend the use of...

Descripció completa

Dades bibliogràfiques

Autors principals:	Eva H. van der Geest, Nina Ajmone Marsan, Dorien Laenens, Philippe J. M. R. Debonnaire, Mathias Claeys, Fauto Pinto, Dulce Brito, Erwan Donal, Steven Droogmans, Nico Van de Veire, Philippe Bertrand, Takeru Nabeta, Francesca Graziani, Madelien V. Regeer
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2025-10-01
Col·lecció:	Journal of Cardiovascular Development and Disease
Matèries:	transthyretin cardiac amyloidosis heart failure medication beta-blockers angiotensin-converting enzyme inhibitors angiotensin II receptor blockers
Accés en línia:	https://www.mdpi.com/2308-3425/12/10/403
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!